JP2021532776A5 - - Google Patents
Info
- Publication number
- JP2021532776A5 JP2021532776A5 JP2021505315A JP2021505315A JP2021532776A5 JP 2021532776 A5 JP2021532776 A5 JP 2021532776A5 JP 2021505315 A JP2021505315 A JP 2021505315A JP 2021505315 A JP2021505315 A JP 2021505315A JP 2021532776 A5 JP2021532776 A5 JP 2021532776A5
- Authority
- JP
- Japan
- Prior art keywords
- poloxamer
- optionally
- pge2
- cells
- hematopoietic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218336A JP2025038075A (ja) | 2018-07-30 | 2024-12-13 | 造血細胞の遺伝子改変のための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712146P | 2018-07-30 | 2018-07-30 | |
| US62/712,146 | 2018-07-30 | ||
| PCT/US2019/044237 WO2020028430A1 (en) | 2018-07-30 | 2019-07-30 | Methods for gene modification of hematopoietic cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218336A Division JP2025038075A (ja) | 2018-07-30 | 2024-12-13 | 造血細胞の遺伝子改変のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532776A JP2021532776A (ja) | 2021-12-02 |
| JP2021532776A5 true JP2021532776A5 (enExample) | 2022-08-04 |
| JP7664829B2 JP7664829B2 (ja) | 2025-04-18 |
Family
ID=69232048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505315A Active JP7664829B2 (ja) | 2018-07-30 | 2019-07-30 | 造血細胞の遺伝子改変のための方法 |
| JP2024218336A Pending JP2025038075A (ja) | 2018-07-30 | 2024-12-13 | 造血細胞の遺伝子改変のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218336A Pending JP2025038075A (ja) | 2018-07-30 | 2024-12-13 | 造血細胞の遺伝子改変のための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210290685A1 (enExample) |
| EP (1) | EP3830248A4 (enExample) |
| JP (2) | JP7664829B2 (enExample) |
| KR (1) | KR20210046004A (enExample) |
| CN (1) | CN112888777A (enExample) |
| AU (1) | AU2019315438B2 (enExample) |
| BR (1) | BR112021001757A2 (enExample) |
| CA (1) | CA3106241A1 (enExample) |
| IL (2) | IL280465B2 (enExample) |
| MX (1) | MX2021001292A (enExample) |
| SG (1) | SG11202100025QA (enExample) |
| WO (1) | WO2020028430A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055862T2 (hu) | 2016-04-20 | 2021-12-28 | Centro De Investig Energeticas | Készítmények és eljárások PKLR fokozott génexpressziójára |
| SG11202002263TA (en) | 2017-10-16 | 2020-04-29 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency |
| WO2019200167A1 (en) | 2018-04-11 | 2019-10-17 | Rocket Pharmaceuticals, Ltd. | Compositions and methods for stem cell transplant |
| MX2020011386A (es) | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| CN115243705A (zh) * | 2020-05-27 | 2022-10-25 | 苏黎世大学 | 新颖的转导增强剂及其用途 |
| KR20230043869A (ko) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법 |
| CN114763563B (zh) * | 2021-01-12 | 2024-04-30 | 深圳华大临床检验中心 | 一种提高慢病毒感染效率的方法 |
| AU2022264498A1 (en) | 2021-04-26 | 2023-09-28 | Strm.Bio Incorporated | Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia |
| WO2025106604A1 (en) * | 2023-11-14 | 2025-05-22 | The University Of North Carolina At Chapel Hill | Compositions and methods relating to antiviral therapeutics |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL261002B2 (en) * | 2016-02-12 | 2024-07-01 | Bluebird Bio Inc | Vcn enhancer compositions and methods of using the same |
| CA3058735A1 (en) | 2016-06-13 | 2017-12-21 | Bluebird Bio, Inc. | Gene therapy of neuronal ceroid lipofuscinoses |
| KR20240151726A (ko) * | 2016-09-08 | 2024-10-18 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | 판코니 빈혈 환자를 위한 유전자 치료 |
| BR112019011635A2 (pt) | 2016-12-06 | 2019-11-12 | Bluebird Bio Inc | terapia genética para mucopolissacaridose, tipo i |
| JP2020500562A (ja) * | 2016-12-06 | 2020-01-16 | ブルーバード バイオ， インコーポレイテッド | ムコ多糖症ｉｉ型のための遺伝子治療 |
-
2019
- 2019-07-30 KR KR1020217005904A patent/KR20210046004A/ko active Pending
- 2019-07-30 WO PCT/US2019/044237 patent/WO2020028430A1/en not_active Ceased
- 2019-07-30 AU AU2019315438A patent/AU2019315438B2/en active Active
- 2019-07-30 CN CN201980049019.6A patent/CN112888777A/zh active Pending
- 2019-07-30 CA CA3106241A patent/CA3106241A1/en active Pending
- 2019-07-30 MX MX2021001292A patent/MX2021001292A/es unknown
- 2019-07-30 EP EP19844952.2A patent/EP3830248A4/en active Pending
- 2019-07-30 IL IL280465A patent/IL280465B2/en unknown
- 2019-07-30 US US17/264,275 patent/US20210290685A1/en active Pending
- 2019-07-30 JP JP2021505315A patent/JP7664829B2/ja active Active
- 2019-07-30 IL IL316185A patent/IL316185A/en unknown
- 2019-07-30 BR BR112021001757-7A patent/BR112021001757A2/pt unknown
- 2019-07-30 SG SG11202100025QA patent/SG11202100025QA/en unknown
-
2024
- 2024-12-13 JP JP2024218336A patent/JP2025038075A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532776A5 (enExample) | ||
| CN112040988A (zh) | 修饰的aav衣壳多肽用于治疗肌肉疾病 | |
| Chen et al. | Combined cord blood stem cells and gene therapy enhances angiogenesis and improves cardiac performance in mouse after acute myocardial infarction | |
| CN103263439B (zh) | Cd34干细胞相关方法和组合物 | |
| CN103687946B (zh) | 用于诱导组织再生的肽及其应用 | |
| E Adair et al. | Lessons learned from two decades of clinical trial experience in gene therapy for Fanconi anemia | |
| US20150139952A1 (en) | Methods, compositions, cells, and kits for treating ischemic injury | |
| HUE035043T2 (en) | A pharmaceutical composition for promoting functional regeneration of damaged tissue | |
| CN102076350A (zh) | 将骨髓来源的多能干细胞动员到末梢循环的药物 | |
| Bortolotti et al. | In vivo functional selection identifies cardiotrophin-1 as a cardiac engraftment factor for mesenchymal stromal cells | |
| JP2023138660A5 (enExample) | ||
| IL285039B1 (en) | Compositions and methods for stimulating natural killer cells | |
| US20240139254A1 (en) | Mesenchymal stem cell having oxidative stress resistance, preparation method therefor, and use thereof | |
| WO2009139413A1 (ja) | サイトカイン誘導キラー細胞含有細胞集団の製造方法 | |
| CN115552019A (zh) | 在髓样细胞和小胶质细胞中特异性表达治疗性蛋白的病毒载体 | |
| WO2021168413A1 (en) | Basic domain-deleted dnase1-like 3 and uses thereof | |
| JP2022542294A5 (enExample) | ||
| KR20220087431A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| TWI881993B (zh) | Ｔ細胞受體及其使用方法 | |
| JP2020517289A5 (enExample) | ||
| EP4711444A2 (en) | Endothelial cells for mitigation of chemotherapy-induced toxicity | |
| KR20220038776A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| JP2025528163A (ja) | キメラｃｄ８－アルファ補助受容体組成物及び使用方法 | |
| JP2025506976A (ja) | 低免疫原性幹細胞、幹細胞から分化または由来した低免疫原性細胞およびこの製造方法 | |
| CN1926234A (zh) | 使用nm23的细胞培养,包含nm23的细胞培养基和在nm23存在下培养的细胞的治疗性用途 |